Curated News
By: NewsRamp Editorial Staff
May 08, 2025
TransCode Therapeutics Advances RNA-Based Cancer Therapeutic in Phase 1a Trial
TLDR
- TransCode Therapeutics advances to Phase 1b dose expansion stage for RNA-based cancer therapeutic with promising early PK/PD data.
- TransCode Therapeutics dosed the third patient in Cohort 4 of Phase 1a trial for TTX-MC138, with expanded enrollment and stable disease seen.
- TransCode Therapeutics aims to defeat cancer through intelligent RNA therapeutics design, potentially unlocking access to novel genetic targets for treating various cancers.
- TransCode Therapeutics' TTX-MC138 shows target engagement with no significant toxicities, offering hope for improved cancer treatments and expanding therapeutic possibilities.
Impact - Why it Matters
This news highlights the progress of TransCode Therapeutics in developing innovative RNA therapeutics for treating metastatic cancer, demonstrating promising results in its Phase 1a trial. The approval of expanded enrollment and positive safety profile signify a step forward in the fight against cancer, offering hope for patients with metastatic tumors.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) announced the dosing of the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138, with 15 patients treated across four dose levels. The Safety Review Committee approved expanded enrollment with no significant toxicities or disease progression. Early PK/PD data confirmed target engagement for TTX-MC138.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, TransCode Therapeutics Advances RNA-Based Cancer Therapeutic in Phase 1a Trial
